Dermal filler compositions for fine line treatment

Patent metadata

Field	Value
Publication number	US-2020353124-A1
Application number	US-202016938504-A
Country	US
Kind code	A1
Filing date	Jul 24, 2020
Priority date	Jun 3, 2011
Publication date	Nov 12, 2020
Grant date	—

Abstract

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.

First claim

What is claimed is:

1 . A dermal filler composition comprising hyaluronic acid and a vitamin C derivative covalently conjugated to the hyaluronic acid.

2 . The dermal filler composition of claim 1 , wherein the vitamin C derivative is conjugated with the hyaluronic acid with a degree of conjugation of between about 3 mol % and about 15 mol %.

3 . The dermal filler composition of claim 1 , wherein the vitamin C derivative is converted into vitamin C in vivo by enzymatic cleavage.

4 . The dermal filler composition of claim 1 , wherein the vitamin C derivative is selected from ascorbic acid 2-glucoside (AA2G), ascorbyl 3 aminopropyl phosphate and sodium ascorbyl phosphate (AA2P).

5 . The dermal filler composition of claim 4 , wherein the vitamin C derivative is ascorbic acid 2-glucoside (AA2G).

6 . The dermal filler composition of claim 4 , wherein the vitamin C derivative is ascorbyl 3-am inopropyl phosphate.

7 . The dermal filler composition of claim 4 , wherein the vitamin C derivative is sodium ascorbyl phosphate (AA2P).

8 . The dermal filler composition of claim 1 , wherein the hyaluronic acid is crosslinked.

9 . The dermal filler composition of claim 8 , wherein the hyaluronic acid is crosslinked with 1,4-butanediol diglycidyl ether (BDDE), pentaerythritol glycidal ether (Star-PEG epoxide), pentaerythritol (3-aminopropyl) ether (Star-PEG amine), or lysine.

10 . The dermal filler composition of claim 9 , wherein the hyaluronic acid is crosslinked with 1,4-butanediol diglycidyl ether (BDDE).

11 . The dermal filler composition of claim 9 , wherein the hyaluronic acid is crosslinked with lysine.

12 . The dermal filler composition of claim 1 , further comprising an anesthetic agent.

13 . The dermal filler composition of claim 12 , wherein the anesthetic agent is lidocaine.

14 . A method for treating a soft tissue condition in a subject in need thereof, the method comprising: administering a dermal filler composition comprising hyaluronic acid and a vitamin C derivative covalently conjugated to the hyaluronic acid.

15 . The method of claim 14 , wherein the soft tissue condition is a wrinkle or scar.

16 . The method of claim 14 , wherein the dermal filler composition releases the vitamin C derivative in the subject in need thereof for at least about 1 month and up to about 20 months.

17 . The method of claim 14 , wherein the vitamin C derivative is covalently conjugated to the hyaluronic acid with BDDE or lysine.

18 . The method of claim 14 , wherein the vitamin C derivative is selected from ascorbic acid 2-glucoside (AA2G), ascorbyl 3 aminopropyl phosphate and sodium ascorbyl phosphate (AA2P).

19 . The method of claim 14 , wherein the vitamin C derivative is AA2G.

20 . The method of claim 14 , wherein the vitamin C derivative is AA2P.

Assignees

• Allergan Ind Sas

Inventors

• Njikang Gabriel N
• Yu Xiaojie
• Liu Futian
• Paliwal Sumit
• Manesis Nicholas J

Classifications

• A61L27/20 Primary

  Polysaccharides · CPC title

• A61Q19/08

  Anti-ageing preparations · CPC title

• A61L2400/06

  Flowable or injectable implant compositions · CPC title

• A61K8/33

  containing oxygen · CPC title

• A61K2800/95

  Involves in-situ formation or cross-linking of polymers · CPC title